At Evotec, I lead a team dedicated to developing therapeutics in the targeted protein degradation space, building on my extensive expertise in protein homeostasis. Our work focuses on discovering novel degrader drugs and my multidisciplinary international team is also making significant progress in creating safer, more potent drug candidates by developing Degrader-Antibody Conjugates for tissue-specific delivery.In addition to my role at Evotec, I serve as an Honorary Senior Lecturer at the University of Glasgow, where I help shape the next generation of scientists. This dual role allows me to bridge the gap between academia and industry, fostering a relationship that accelerates scientific discovery and enriches educational experiences.